| Literature DB >> 25493337 |
Elise Emeville1, Arnaud Giusti, Xavier Coumoul, Jean-Pierre Thomé, Pascal Blanchet, Luc Multigner.
Abstract
BACKGROUND: Long-term exposure to persistent pollutants with hormonal properties (endocrine-disrupting chemicals; EDCs) may contribute to the risk of prostate cancer (PCa). However, epidemiological evidence remains limited.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25493337 PMCID: PMC4384204 DOI: 10.1289/ehp.1408407
Source DB: PubMed Journal: Environ Health Perspect ISSN: 0091-6765 Impact factor: 9.031
Detection and concentrations of organochlorine pollutants in plasma samples from the study population [μg/L (μg/g lipids)].
| Organochlorine | Detection frequency (%) | Percentile | Maximum | |||
|---|---|---|---|---|---|---|
| 10th | 25th | 50th | 75th | |||
| Controls | ||||||
| 36.2 | < LOD | < LOD | < LOD | 0.07 (0.01) | 1.7 (0.32) | |
| 24.0 | < LOD | < LOD | < LOD | 0.04 (0.008) | 0.84 (0.15) | |
| 96.2 | 0.39 (0.07) | 0.98 (0.18) | 2.06 (0.38) | 4.37 (0.75) | 27.8 (6.7) | |
| PCB-28 | 54.5 | < LOD | < LOD | 0.07 (0.01) | 0.28 (0.05) | 8.0 (1.4) |
| PCB-52 | 42.6 | < LOD | < LOD | < LOD | 0.28 (0.05) | 12.7 (2.5) |
| PCB-101 | 52.1 | < LOD | < LOD | 0.05 (0.009) | 0.13 (0.02) | 1.1 (0.21) |
| PCB-118 | 59.2 | < LOD | < LOD | 0.08 (0.01) | 0.20 (0.03) | 3.3 (0.9) |
| PCB-138 | 97.4 | 0.18 (0.03) | 0.31 (0.06) | 0.53 (0.10) | 0.90 (0.16) | 12.2 (2.4) |
| PCB-153 | 98.2 | 0.24 (0.05) | 0.48 (0.09) | 0.85 (0.15) | 1.47 (0.26) | 16.5 (3.5) |
| PCB-180 | 97.4 | 0.23 (0.04) | 0.39 (0.07) | 0.64 (0.12) | 1.03 (0.18) | 10.3 (2.0) |
| α-HCH | 35.9 | < LOD | < LOD | < LOD | 0.08 (0.01) | 1.6 (0.32) |
| β-HCH | 43.5 | < LOD | < LOD | < LOD | 0.09 (0.02) | 1.9 (0.30) |
| γ-HCH | 27.7 | < LOD | < LOD | < LOD | 0.08 (0.01) | 1.8 (0.41) |
| Chlordecone | 84.1 | < LOD | 0.17 (0.03) | 0.42 (0.08) | 0.83 (0.15) | 49.2 (8.8) |
| Cases | ||||||
| 29.3 | < LOD | < LOD | < LOD | 0.06 (0.01) | 2.5 (0.43) | |
| 20.1 | < LOD | < LOD | < LOD | 0.03 (0.006) | 0.99 (0.15) | |
| 95.5 | 0.40 (0.08) | 1.11 (0.22) | 2.55 (0.50) | 5.74 (1.07) | 40.1 (6.6) | |
| PCB-28 | 52.6 | < LOD | < LOD | 0.06 (0.01) | 0.29 (0.05) | 6.8 (1.1) |
| PCB-52 | 49.3 | < LOD | < LOD | < LOD | 0.38 (0.07) | 6.7 (1.1) |
| PCB-101 | 51.2 | < LOD | < LOD | 0.05 (0.009) | 0.13 (0.02) | 1.2 (0.17) |
| PCB-118 | 62.0 | < LOD | < LOD | 0.08 (0.02) | 0.18 (0.03) | 2.4 (0.52) |
| PCB-138 | 97.9 | 0.17 (0.03) | 0.30 (0.06) | 0.54 (0.10) | 0.87 (0.18) | 6.7 (1.1) |
| PCB-153 | 98.8 | 0.23 (0.04) | 0.41 (0.06) | 0.78 (0.10) | 1.24 (0.18) | 8.4 (1.3) |
| PCB-180 | 97.2 | 0.25 (0.05) | 0.37 (0.07) | 0.62 (0.12) | 0.90 (0.18) | 6.2 (1.0) |
| α-HCH | 28.5 | < LOD | < LOD | < LOD | 0.05 (0.01) | 1.2 (0.20) |
| β-HCH | 38.0 | < LOD | < LOD | < LOD | 0.11 (0.02) | 2.2 (0.46) |
| γ-HCH | 18.4 | < LOD | < LOD | < LOD | < LOD | 0.65 (0.13) |
| Chlordecone | 82.8 | < LOD | 0.18 (0.03) | 0.43 (0.08) | 0.94 (0.18) | 26.4 (4.1) |
Baseline characteristics of the study population.
| Characteristic | Cases [no. (%)] | Controls [no. (%)] | |
|---|---|---|---|
| Age (years) [mean (range)] | 65.9 (52.6–79.1) | 60.9 (48.0–77.1) | < 0.001 |
| Caribbean origin | |||
| French West Indies | 556 (96.5) | 598 (91.3) | < 0.001 |
| Haiti or Dominica | 20 (3.5) | 57 (8.7) | |
| Education | |||
| Primary | 349 (61.0) | 362 (57.5) | 0.04 |
| Secondary | 147 (25.7) | 201 (32.0) | |
| High school and higher | 76 (13.3) | 66 (10.5) | |
| Missing data | 4 | 26 | |
| Body mass index (kg/m2) | |||
| < 25 | 241 (44.5) | 306 (46.9) | 0.54 |
| 25 to < 30 | 240 (44.3) | 268 (41.1) | |
| ≥ 30 | 61 (11.2) | 78 (12.0) | |
| Missing data | 34 | 3 | |
| Waist-to-hip ratio | |||
| ≤ 0.95 | 196 (54.4) | 455 (69.8) | < 0.001 |
| > 0.95 | 164 (45.6) | 197 (30.2) | |
| Missing data | 216 | 3 | |
| Smoking | |||
| Never | 355 (62.2) | 410 (62.9) | 0.80 |
| Former or current | 216 (37.8) | 242 (37.1) | |
| Missing data | 5 | 3 | |
| Alcohol consumption | |||
| Never | 74 (13.0) | 112 (17.4) | 0.03 |
| Former or current | 494 (87.0) | 536 (82.6) | |
| Missing data | 8 | 12 | |
| Type 2 diabetes | |||
| No | 457 (81.5) | 556 (87.4) | 0.004 |
| Yes | 104 (18.5) | 80 (12.6) | |
| Missing data | 15 | 19 | |
| Past residence in Western countries | |||
| No | 403 (70.0) | 498 (76.3) | 0.01 |
| Yes | 173 (30.0) | 155 (23.7) | |
| Missing data | — | 2 | |
| PSA screening history | |||
| No | 278 (48.4) | 572 (87.3) | < 0.001 |
| Yes | 296 (51.6) | 83 (12.7) | |
| Missing data | 2 | — | |
| Family history of prostate cancer | |||
| No | 317 (55.9) | 498 (78.2) | < 0.001 |
| Yes | 144 (25.4) | 66 (10.4) | |
| Do not know | 106 (18.6) | 74 (11.4) | |
| Missing data | 9 | 18 | |
| Gleason score | |||
| < 7 or 3 + 4 | 462 (82.1) | — | |
| > 7 or 4 + 3 | 101(17.9) | — | |
| Missing data | 9 | ||
| Clinical stage (T, N, M) | |||
| T1c or T2 and N0 and M0 | 485 (87.4) | — | |
| T3 or T4, or N+ or M+ | 70 (12.6) | — | |
| Missing data | 21 | ||
ORs (95% CIs) of prostate cancer according to quintile of DDE and PCB-153 exposure.
| Exposure | Controls ( | Cases ( | Crude OR (95% CI) | Adjusted OR |
|---|---|---|---|---|
| DDE (μg/L) | ||||
| < 0.79 | 131 | 106 | 1.0 (reference) | 1.0 (reference) |
| 0.79–1.62 | 130 | 96 | 0.91 (0.63, 1.62) | 0.96 (0.66, 1.42) |
| 1.63–2.89 | 133 | 111 | 1.03 (0.72, 1.48) | 1.05 (0.71, 1.55) |
| 2.90–5.18 | 131 | 104 | 0.98 (0.68, 1.41) | 1.02 (0.67, 1.53) |
| ≥ 5.19 | 130 | 159 | 1.51 (1.07, 2.13) | 1.53 (1.02, 2.30) |
| 0.003 | 0.01 | |||
| PCB-153 (μg/L) | ||||
| < 0.41 | 132 | 141 | 1.0 (reference) | 1.0 (reference) |
| 0.41–0.69 | 132 | 109 | 0.77 (0.55, 1.09) | 0.56 (0.38, 0.83) |
| 0.70–1.07 | 134 | 135 | 0.94 (0.67, 1.32) | 0.67 (0.46, 0.99) |
| 1.08–1.70 | 131 | 110 | 0.79 (0.55, 1.11) | 0.45 (0.30, 0.63) |
| ≥ 1.71 | 126 | 81 | 0.60 (0.42, 0.87) | 0.30 (0.19, 0.47) |
| 0.01 | < 0.001 | |||
OR (95% CIs) for DDE and PCB-153, and prostate cancer by Gleason score and clinical stage.
| Exposure | Controls ( | Low grade ( | Low-grade OR | High grade ( | High-grade OR | Localized ( | Localized OR | Advanced ( | Advanced OR | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| DDE (μg/L) | |||||||||||
| < 1.37 | 218 | 144 | 1.0 (reference) | 20 | 1.0 (reference) | 145 | 1.0 (reference) | 15 | 1.0 (reference) | ||
| 1.37–3.41 | 218 | 151 | 1.06 (0.77, 1.47) | 34 | 1.55 (0.85, 2.85) | 0.23 | 160 | 1.11 (0.81, 1.52) | 23 | 1.44 (0.69, 2.98) | 0.50 |
| ≥ 3.42 | 219 | 167 | 1.18 (0.84, 1.65) | 47 | 1.92 (1.04, 3.54) | 0.13 | 180 | 1.26 (0.91, 1.76) | 32 | 1.39 (0.66, 2.93) | 0.83 |
| 0.33 | 0.06 | 0.18 | 0.55 | ||||||||
| PCB-153 (μg/L) | |||||||||||
| < 0.60 | 218 | 183 | 1.0 (reference) | 28 | 1.0 (reference) | 181 | 1.0 (reference) | 22 | 1.0 (reference) | ||
| 0.61–1.24 | 216 | 174 | 0.78 (0.57, 1.06) | 39 | 1.11 (0.63, 1.95) | 0.22 | 189 | 0.83 (0.61, 1.14) | 23 | 0.84 (0.42, 1.68) | 0.97 |
| ≥ 1.25 | 221 | 105 | 0.35 (0.25, 0.51) | 34 | 0.69 (0.37, 1.29) | 0.04 | 115 | 0.38 (0.27, 0.55) | 25 | 0.64 (0.30, 1.35) | 0.19 |
| < 0.001 | 0.10 | < 0.001 | 0.28 | ||||||||